NA
ORMP icon

Nordwand Advisors’s Oramed Pharmaceuticals ORMP Stock Holding History

Nordwand Advisors’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,000
Closed -$2.44K – 131
2024
Q3 		$2.44K Buy
+1,000
New +$2.44K ﹤0.01% 116

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Nordwand Advisors's ORMP Position: Q4 2024 in Review

Nordwand Advisors sold out of Oramed Pharmaceuticals (ORMP) in Q4 2024, closing a stake of 1,000 shares — an estimated $2.44K sold.

Nordwand Advisors first reported a position in ORMP in Q3 2024 and held it in 1 quarter. The position peaked at $2.44K in Q3 2024. 56 funds tracked by Wall St. Rank hold ORMP as of Q4 2024.

  • Nordwand Advisors reported no remaining Oramed Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Nordwand Advisors sold 1,000 Oramed Pharmaceuticals shares in Q4 2024, an estimated $2.44K.
  • Nordwand Advisors first reported a position in Oramed Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Nordwand Advisors's Oramed Pharmaceuticals position peaked at $2.44K in Q3 2024.
  • 56 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q4 2024.

Based on Nordwand Advisors's 13F filing for Q4 2024, filed 7 Feb 2025.